CTLA4 and neoplasm: 1) When ICIs inhibit CTLA-4/PD-1/PD-L1, it releases the body’s “immune checkpoint.” While strongly activating the immunity of T cells to tumor cells, it also leads to the kidney’s tolerance of endogenous antigen decline, which triggers AKI.